drugset

drugset / Trial / NCT02427126

Apixaban for Treatment of Embolic Stroke of Undetermined Source

NCT02427126 ↗

Phase 3 Completed 352 enrolled University Hospital Tuebingen Bristol-Myers Squibb · collab Medtronic · collab ZKS and IKEaB Tübingen · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

Multicentre (national, Germany), randomized (2x2 factorial), open, parallel group, active controlled, efficacy study (phase III)

Timeline

Start: 2015-12
Primary completion: 2020-08
Completion: 2021-09

Publications

Geisler T, Keller T, Martus P, Poli K, Serna-Higuita LM, Schreieck J, Gawaz M, Tunnerhoff J, Bombach P, Nagele T, Klose U, Aidery P, Groga-Bada P, Kraft A, Hoffmann F, Hobohm C, Naupold K, Niehaus L, Wolf M, Bazner H, Liman J, Wachter R, Kimmig H, Jung W, Huber R, Feurer R, Lindner A, Althaus K, Bode FJ, Petzold GC, Nguyen TN, Mac Grory B, Schrag M, Purrucker JC, Zuern CS, Ziemann U, Poli S; ATTICUS Investigators. Apixaban versus Aspirin for Embolic Stroke of Undetermined Source. NEJM Evid. 2024 Jan;3(1):EVIDoa2300235. doi: 10.1056/EVIDoa2300235. Epub 2023 Dec 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apixaban	Small molecule	5 mg	Oral
Comparator	Aspirin	Small molecule	100 mg	—

Indications

No indication recorded.